Allergan and Cigna Keep Shareholders Anxious Ahead of Earnings

Allergan, Inc. (NYSE:AGN) will unveil its latest earnings on Thursday, February 2, 2012. The average estimate of analysts is for profit of $1 per share, a rise of 13.6% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. Analysts are projecting profit to rise by 15.2% versus last year to $3.64.

The company’s quarterly results have come in above estimates for the last three quarters. Last quarter, the company booked net income of 92 cents per share versus a mean estimate of profit of 90 cents per share. On average, analysts predict $1.41 billion in revenue this quarter, a rise of 7.6% from the year ago quarter. Analysts are forecasting total revenue of $5.43 billion for the year, a rise of 11.3% from last year’s revenue of $4.88 billion.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH), ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA), Endo Pharmaceuticals (NASDAQ:ENDP), Medicis Pharmaceutical Corp. (NYSE:MRX), Akorn, Inc. (NASDAQ:AKRX), Novartis AG (NYSE:NVS), GlaxoSmithKline plc (NYSE:GSK), Merck & Co., Inc. (NYSE:MRK), and Hospira, Inc. (NYSE:HSP).

Cigna Corporation (NYSE:CI) will unveil its latest earnings on Thursday, February 2, 2012. The average estimate of analysts is for net income of $1.18 per share, a rise of 2.6% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.19. Between one and three months ago, the average estimate was unchanged. It has since dropped over the last month. For the year, analysts are projecting profit of $5.29 per share, a rise of 14% from last year.

The company missed estimates last quarter after beating forecasts in the prior two. In the third quarter, the company reported net income of $1.20 per share versus a mean estimate of profit of $1.22 per share. In the second quarter, the company beat estimates by 24 cents. On average, analysts predict $5.51 billion in revenue this quarter, a rise of 1.5% from the year ago quarter. Analysts are forecasting total revenue of $21.87 billion for the year, a rise of 2.9% from last year’s revenue of $21.25 billion.

Competitors to Watch: Humana Inc. (NYSE:HUM), WellPoint, Inc. (NYSE:WLP), Aetna Inc. (NYSE:AET), UnitedHealth Group Inc. (NYSE:UNH), Health Net, Inc. (NYSE:HNT), Universal American Corp. (NYSE:UAM), HealthSpring, Inc (NYSE:HS), Molina Healthcare, Inc. (NYSE:MOH), Coventry Health Care, Inc. (NYSE:CVH), and WellCare Health Plans, Inc. (NYSE:WCG).

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com